COSCIENS Biopharma Inc. (CSCIF) stock
CSCIFOTCPerfumes, Cosmetics & Other Toilet PreparationsFiscal year ends December 31
$6.49+0.00 (0.00%)
Close on Oct 19, 2026Market cap $24.10MP/E –Yield –
COSCIENS Biopharma revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
COSCIENS Biopharma's revenue for the twelve months ending Mar 31, 2026 was $7.89M, down 11.6% year over year. For fiscal 2025 it was $7.50M, down 21.8% from the year before. Over ten years it grew 30.0% a year on average. The highest annual figure on record is $26.88M in fiscal 2018.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.50M | -21.8% |
| FY2024 | Dec 31, 2024 | $9.59M | +34.2% |
| FY2023 | Dec 31, 2023 | $7.14M | -51.0% |
| FY2022 | Dec 31, 2022 | $14.57M | +177.0% |
| FY2021 | Dec 31, 2021 | $5.26M | +44.0% |
| FY2020 | Dec 31, 2020 | $3.65M | +586.5% |
| FY2019 | Dec 31, 2019 | $532.00K | -98.0% |
| FY2018 | Dec 31, 2018 | $26.88M | +2812.4% |
| FY2017 | Dec 31, 2017 | $923.00K | +1.3% |
| FY2016 | Dec 31, 2016 | $911.00K | +67.2% |
| FY2015 | Dec 31, 2015 | $545.00K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2026 | Mar 31, 2026 | $1.89M | +36.1% |
| Q4 FY2025 | Dec 31, 2025 | $1.77M | -46.8% |
| Q3 FY2025 | Sep 30, 2025 | $1.48M | -20.7% |
| Q2 FY2025 | Jun 30, 2025 | $2.75M | +17.6% |
| Q1 FY2025 | Mar 31, 2025 | $1.39M | -32.6% |
| Q4 FY2024 | Dec 31, 2024 | $3.32M | +173.6% |
| Q3 FY2024 | Sep 30, 2024 | $1.87M | -4.1% |
| Q2 FY2024 | Jun 30, 2024 | $2.34M | +67.9% |
| Q1 FY2024 | Mar 31, 2024 | $2.06M | -3.3% |
| Q4 FY2023 | Dec 31, 2023 | $1.21M | -89.4% |
| Q3 FY2023 | Sep 30, 2023 | $1.95M | +4.9% |
| Q2 FY2023 | Jun 30, 2023 | $1.39M | – |
| Q1 FY2023 | Mar 31, 2023 | $2.13M | +40.3% |
| Q4 FY2022 | Dec 31, 2022 | $11.42M | +1094.2% |
| Q3 FY2022 | Sep 30, 2022 | $1.86M | +76.8% |
| Q2 FY2022 | Jun 30, 2022 | -$222.00K | -114.0% |
| Q1 FY2022 | Mar 31, 2022 | $1.52M | -9.1% |
| Q4 FY2021 | Dec 31, 2021 | $956.00K | -59.6% |
| Q3 FY2021 | Sep 30, 2021 | $1.05M | +721.9% |
| Q2 FY2021 | Jun 30, 2021 | $1.58M | +2229.4% |
| Q1 FY2021 | Mar 31, 2021 | $1.67M | +53.0% |
| Q4 FY2020 | Dec 31, 2020 | $2.37M | +13044.4% |
| Q3 FY2020 | Sep 30, 2020 | $128.00K | -54.8% |
| Q2 FY2020 | Jun 30, 2020 | $68.00K | -64.9% |
| Q1 FY2020 | Mar 31, 2020 | $1.09M | +2845.9% |
| Q4 FY2019 | Dec 31, 2019 | $18.00K | -98.7% |
| Q3 FY2019 | Sep 30, 2019 | $283.00K | -57.3% |
| Q2 FY2019 | Jun 30, 2019 | $194.00K | +15.5% |
| Q1 FY2019 | Mar 31, 2019 | $37.00K | – |
| Q4 FY2018 | Dec 31, 2018 | $1.39M | – |
| Q3 FY2018 | Sep 30, 2018 | $663.00K | – |
| Q2 FY2018 | Jun 30, 2018 | $168.00K | – |
See a number that looks wrong?